Sardegna
Copyright policy )Sardegna
In Sardinia region 45,5% of women (aged 25-64) are screened regularly, meaning every 3 years. Considering regional tariffs and vaccine acquisition cost, the vaccination of 12-year-old girls with a 90% coverage could prevent 38 cases of cervicocarcinoma and 15 related deaths and thus results to be cost-effective (15.347 €/QALY). When the vaccination programme is extended to 16-year-old girls a further 41 cancer cases and 18 deaths could be prevented, with a very similar cost-effectiveness ratio. In Sardinia region, the net cost for woman vaccinated is 148 € for the single cohort and 152 € for the multiple cohort.
- University of Pavia Italy
- GlaxoSmithKline (Belgium) Belgium
- GlaxoSmithKline (Italy) Italy
- Università Luigi Bocconi Italy
Medicine (General), R5-920, economic & clinical impact, Pharmacoeconomics; Health economics, hpv vaccination, sardinia, Sardinia; HPV vaccination; Economic & clinical impact
Medicine (General), R5-920, economic & clinical impact, Pharmacoeconomics; Health economics, hpv vaccination, sardinia, Sardinia; HPV vaccination; Economic & clinical impact
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!